Evinacumab in Patients with Refractory Hypercholesterolemia-Reference-Cited by-同舟云学术

Evinacumab in Patients with Refractory Hypercholesterolemia

Published:2020-12-10 Issue:24 Volume:383 Page:2307-2319
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Rosenson Robert S.¹,Burgess Lesley J.¹,Ebenbichler Christoph F.¹,Baum Seth J.¹,Stroes Erik S.G.¹,Ali Shazia¹,Khilla Nagwa¹,Hamlin Robert¹,Pordy Robert¹,Dong Yuping¹,Son Vladimir¹,Gaudet Daniel¹

Affiliation:

1. From the Icahn School of Medicine at Mount Sinai, New York (R.S.R.), and Regeneron Pharmaceuticals, Tarrytown (S.A., N.K., R.H., R.P., Y.D., V.S.) — both in New York; TREAD Research, Cardiology Unit, Department of Internal Medicine and Tygerberg Hospital, Parow, South Africa (L.J.B.); the Department of Internal Medicine I, Medical University Innsbruck, Innsbruck, Austria (C.F.E.); Excel Medical Clinical Trials, Department of Integrated Medical Sciences, Charles E. Schmidt College of Medicine, Florida...

Funder

Regeneron Pharmaceuticals

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa2031049

Cited by 206 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia;New England Journal of Medicine;2024-09-12

2. Emerging Trends and Innovations in the Treatment and Diagnosis of Atherosclerosis and Cardiovascular Disease: A Comprehensive Review towards Healthier Aging;Pharmaceutics;2024-08-03

3. Recent advances in targeted therapy for inflammatory vascular diseases;Journal of Controlled Release;2024-08

4. Interaction Between Primary Hyperlipidemias and Type 2 Diabetes: Therapeutic Implications;Diabetes Therapy;2024-07-30

5. Lipoprotein Apheresis: An Established Therapeutic Modality for Homozygous Familial Hypercholesterolemia Patients Refractory to PCSK9 Inhibitors: A Case Report and Literature Review;2024-07-29